Evidence map›Paper›PMID 25332235›Full record

ArticleMolecular and cellular biology2015

Substrate trapping proteomics reveals targets of the βTrCP2/FBXW11 ubiquitin ligase.

Tai Young Kim, Priscila F Siesser, Kent L Rossman, Dennis Goldfarb, Kathryn Mackinnon, Feng Yan, XianHua Yi, Michael J MacCoss, Randall T Moon, Channing J Der and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. SCFBiomedicines · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Extracellular matrix stiffness regulates degradation of MST2 via SCFBiochimica et biophysica acta. General subjects · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tai Young KimDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Priscila F SiesserDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kent L RossmanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Dennis GoldfarbDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kathryn MackinnonDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Feng YanDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
XianHua YiDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA.
Michael J MacCossDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA.
Randall T MoonDepartment of Pharmacology and HHMI, University of Washington, Seattle, Washington, USA.
Channing J DerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael B MajorDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ben_major@med.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2021
$20.7M
Exploitation of Near-Haploid Human Cells for Functional Gene DiscoveryDP2OD007149 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAJOR, MICHAEL BENJAMIN · 2010 to 2010
$2.2M
NIGMS NIH HHS P41 GM103533NIH HHS DP2 OD007149
6 · The paper itself

Abstract

Defining the full complement of substrates for each ubiquitin ligase remains an important challenge. Improvements in mass spectrometry instrumentation and computation and in protein biochemistry methods have resulted in several new methods for ubiquitin ligase substrate identification. Here we used the parallel adapter capture (PAC) proteomics approach to study βTrCP2/FBXW11, a substrate adaptor for the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex. The processivity of the ubiquitylation reaction necessitates transient physical interactions between FBXW11 and its substrates, thus making biochemical purification of FBXW11-bound substrates difficult. Using the PAC-based approach, we inhibited the proteasome to "trap" ubiquitylated substrates on the SCF(FBXW11) E3 complex. Comparative mass spectrometry analysis of immunopurified FBXW11 protein complexes before and after proteasome inhibition revealed 21 known and 23 putatively novel substrates. In focused studies, we found that SCF(FBXW11) bound, polyubiquitylated, and destabilized RAPGEF2, a guanine nucleotide exchange factor that activates the small GTPase RAP1. High RAPGEF2 protein levels promoted cell-cell fusion and, consequently, multinucleation. Surprisingly, this occurred independently of the guanine nucleotide exchange factor (GEF) catalytic activity and of the presence of RAP1. Our data establish new functions for RAPGEF2 that may contribute to aneuploidy in cancer. More broadly, this report supports the continued use of substrate trapping proteomics to comprehensively define targets for E3 ubiquitin ligases. All proteomic data are available via ProteomeXchange with identifier PXD001062.

Indexed as

beta-Transducin Repeat-Containing ProteinsGuanine Nucleotide Exchange FactorsHEK293 CellsHumansMutagenesisMutagenesis, Site-DirectedNeoplasmsNerve Tissue ProteinsPhenotypeProteasome Endopeptidase ComplexProteomeProteomicsRNA, Small InterferingShelterin ComplexTelomere-Binding ProteinsUbiquitinbeta-Transducin Repeat-Containing ProteinsFBXW11 protein, humanGuanine Nucleotide Exchange FactorsNerve Tissue ProteinsProteasome Endopeptidase ComplexProteomeRAPGEF2 protein, humanRNA, Small InterferingShelterin ComplexTelomere-Binding ProteinsTERF2IP protein, humanUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID25332235
PMCPMC4295375
OpenAlexW2157761646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.